JP2017518306A - 結晶性β−Ｄ−ニコチンアミドリボシドの製造および使用 - Google Patents

結晶性β−Ｄ−ニコチンアミドリボシドの製造および使用 Download PDF

Info

Publication number
JP2017518306A
JP2017518306A JP2016570860A JP2016570860A JP2017518306A JP 2017518306 A JP2017518306 A JP 2017518306A JP 2016570860 A JP2016570860 A JP 2016570860A JP 2016570860 A JP2016570860 A JP 2016570860A JP 2017518306 A JP2017518306 A JP 2017518306A
Authority
JP
Japan
Prior art keywords
nicotinamide riboside
chloride
pyridin
disease
ion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016570860A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017518306A5 (enExample
Inventor
ブルース、シチェパンキーウィクス
カルステン、コペッチュ
ロバート、ビー．ペルニ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of JP2017518306A publication Critical patent/JP2017518306A/ja
Publication of JP2017518306A5 publication Critical patent/JP2017518306A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
JP2016570860A 2014-06-02 2015-06-02 結晶性β−Ｄ−ニコチンアミドリボシドの製造および使用 Pending JP2017518306A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462006434P 2014-06-02 2014-06-02
US62/006,434 2014-06-02
PCT/IB2015/054181 WO2015186068A1 (en) 2014-06-02 2015-06-02 Preparation and use of crystalline beta-d-nicotinamide riboside

Publications (2)

Publication Number Publication Date
JP2017518306A true JP2017518306A (ja) 2017-07-06
JP2017518306A5 JP2017518306A5 (enExample) 2018-07-12

Family

ID=53276953

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016570860A Pending JP2017518306A (ja) 2014-06-02 2015-06-02 結晶性β−Ｄ−ニコチンアミドリボシドの製造および使用

Country Status (10)

Country Link
US (1) US10316054B2 (enExample)
EP (1) EP3149016A1 (enExample)
JP (1) JP2017518306A (enExample)
KR (1) KR20170012449A (enExample)
CN (1) CN106536535A (enExample)
AU (1) AU2015270130A1 (enExample)
CA (1) CA2950727A1 (enExample)
MX (1) MX2016015997A (enExample)
RU (1) RU2016149764A (enExample)
WO (1) WO2015186068A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021506898A (ja) * 2017-12-22 2021-02-22 エリシウム ヘルス，インコーポレーテッド ニコチンアミドリボシドクロリドの結晶形態
JP2022541058A (ja) * 2019-07-19 2022-09-21 バイオシント アクチェンゲゼルシャフト ニコチンアミドリボフラノシド塩の製造方法、ニコチンアミドリボフラノシド塩自体、およびその使用
JP2022542546A (ja) * 2020-06-19 2022-10-05 ボンタック バイオエンジニアリング（シェンゼン） カンパニー リミテッド ニコチンアミドを原料としてニコチンアミドモノヌクレオチドを調製する方法
JP2023510034A (ja) * 2020-04-03 2023-03-10 深▲せん▼市迪克曼科技開発有限公司 ニコチンアミドリボースの有機酸塩、その組成物及び製造方法
JP2024503442A (ja) * 2021-01-19 2024-01-25 バイオシント アクチェンゲゼルシャフト 塩メタセシスによるニコチンアミドリボフラノシド塩の製造方法、そのトシレート塩の結晶形態及びそのクロリド：ヨージド塩の共結晶化した形態

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2956163C (en) 2014-07-24 2023-01-10 W.R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
ES2963057T3 (es) * 2015-03-09 2024-03-25 Grace W R & Co Forma cristalina de ribósido de nicotinamida
US9855289B2 (en) 2015-08-05 2018-01-02 Metro International Biotech, Llc Nicotinamide mononucleotide derivatives and their uses
WO2017042198A2 (en) * 2015-09-08 2017-03-16 Ecole Polytechnique Federale De Lausanne (Epfl) Agents and methods using thereof for the prevention and treatment of stem cell muscle disorders
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
US10611790B2 (en) 2015-11-02 2020-04-07 Mitobridge, Inc. Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases
CN109562104A (zh) * 2016-04-14 2019-04-02 可劳迈戴斯有限公司 烟酰胺核苷、烟酸核苷、烟酰胺单核苷酸、和烟碱基化合物衍生物在婴儿配方中的用途
GB2553001A (en) * 2016-08-19 2018-02-21 The Queen's Univ Of Belfast Lactone intermediates of nicotinamide riboside and nicotinate riboside
JP7132907B2 (ja) 2016-08-22 2022-09-07 エリジウム・ヘルス・インコーポレイテッド ニコチンアミドリボシド及びプテロスチルベン組成物及び神経変性障害の治療方法
NZ803738A (en) 2016-11-11 2024-05-31 Chromadex Inc Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
EP3554285A4 (en) 2016-11-29 2021-01-20 University of Iowa Research Foundation USE OF NAD PRECURSORS TO IMPROVE THE HEALTH OF MOTHER AND / OR OFFspring
US20190328761A1 (en) 2016-12-21 2019-10-31 Newsouth Innovations Pty Limited Methods for enhancing vascular density
EP3568488A4 (en) * 2017-01-13 2020-09-23 The Regents of The University of Colorado, A Body Corporate METHODS OF TREATMENT OF HYPERTENSION AND ARTERIAL RIGIDITY
US11129843B2 (en) 2017-04-24 2021-09-28 Elysium Health, Inc. Treating and preventing kidney damage
EP3624808A4 (en) * 2017-05-18 2021-03-03 Elysium Health, Inc. PROCEDURES AND COMPOSITIONS FOR IMPROVED SLEEP
US11286274B2 (en) 2017-06-19 2022-03-29 Mitopower Llc Nicotinamide riboside derivatives and their uses
WO2018236747A1 (en) * 2017-06-21 2018-12-27 Yale University COMPOUNDS AND COMPOSITIONS FOR EXTENDING THE DURATION OF A SUBJECT
JP2020526511A (ja) * 2017-06-30 2020-08-31 エリジウム・ヘルス・インコーポレイテッド ニコチンアミドリボシドの合成方法
KR101990681B1 (ko) * 2017-07-05 2019-06-18 가천대학교 산학협력단 편두통 진단용 바이오마커 및 상기 바이오마커를 이용한 편두통 진단방법
KR101982923B1 (ko) * 2017-07-05 2019-05-27 가천대학교 산학협력단 편두통 진단용 바이오마커 및 상기 바이오마커를 이용한 편두통 진단방법
WO2019133815A1 (en) 2017-12-28 2019-07-04 Kansas State University Research Foundation Nicotinamide riboside treatments of domesticated meat animals
WO2019152416A1 (en) 2018-01-30 2019-08-08 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
CN110283221A (zh) * 2018-03-19 2019-09-27 药源药物化学（上海）有限公司 杂环化合物的制备和纯化方法
WO2019209840A1 (en) * 2018-04-23 2019-10-31 Elysium Health, Inc. Methods and compositions for treating rheumatoid arthritis
CN110452277A (zh) * 2018-05-07 2019-11-15 明特奇点医疗科技(成都)有限公司 一种烟酰胺核糖的制备方法
CN112135833A (zh) * 2018-05-18 2020-12-25 弗·哈夫曼-拉罗切有限公司 (硫代)烟酰胺呋喃核糖苷盐及其组合物、制备方法和用途
BR112020023132A2 (pt) * 2018-06-21 2021-02-09 Société des Produits Nestlé S.A. composições e métodos que usam um precursor de nicotinamida adenina dinucleotídeo (nad+) e pelo menos uma cetona ou um precursor de cetona
CN108774278A (zh) * 2018-09-10 2018-11-09 张洪喜 一种制备尼克酰胺核苷盐的方法
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
WO2020131578A2 (en) 2018-12-17 2020-06-25 Mitopower Llc Nicotinyl riboside compounds and their uses
US10618927B1 (en) 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
US20200397807A1 (en) 2019-06-18 2020-12-24 MitoPower, LLC Nicotinyl riboside compounds and their uses
PH12022551051A1 (en) * 2019-11-01 2023-05-03 Celagenex Res India Pvt Ltd Synergistic nutritional compositions for treating cerebrovascular diseases
WO2021180739A1 (en) * 2020-03-09 2021-09-16 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of viral and bacterial infections
CN111808156A (zh) * 2020-07-15 2020-10-23 许昌远志生物科技有限公司 一种β-烟酰胺核糖氯化物的晶型1A、晶型1B及其制备方法
US20230263817A1 (en) * 2020-08-28 2023-08-24 University Of Washington High dose nicotinamide adenine dinucleotide (nad) precursor regimens for reduction of inflammation in human patients with preexisting inflammation
CN112028954B (zh) * 2020-09-14 2022-04-29 浩宇康宁健康科技（湖北）有限公司 烟酰胺核糖的制备方法
CA3206155A1 (en) * 2021-01-29 2022-08-04 ChromaDex Inc. Ethyl cellulose based coatings for microencapsulation of nicotinamide riboside and other nicotinyl riboside compounds
CA3219033A1 (en) 2021-05-27 2022-12-01 Metro International Biotech, Llc Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use
CN113943333B (zh) * 2021-10-09 2023-07-14 广东生命源科技有限公司 一种氢化烟酰胺核糖的制备方法及应用
CN118176006A (zh) * 2021-10-27 2024-06-11 益力舒健康公司 治疗更年期综合征的方法
WO2023147161A2 (en) * 2022-01-31 2023-08-03 New Frontier Bio, Inc. Nicotinate and nicotinamide riboside-based compounds and derivatives thereof
CN114577935B (zh) * 2022-03-03 2024-07-23 中科谱研（北京）科技有限公司 一种胶囊中烟酰胺核糖氯化物的分离检测方法
EP4493572A4 (en) * 2022-03-15 2025-11-19 Chromadex Inc PROCESSES FOR THE PRODUCTION OF BETA NICOTINAMIDE TRIACETATE RIBOSIDE CRYSTALLINE
CN116621898A (zh) * 2022-04-13 2023-08-22 深圳市迪克曼科技开发有限公司 烟酰胺核糖的有机酸盐及其结晶形态、制备方法与用途
CN115287278B (zh) * 2022-06-17 2023-11-10 武汉真福医药股份有限公司 一种枯草芽孢杆菌纤溶酶及其制备方法和抗氧化溶血栓组合物
WO2024160239A1 (zh) 2023-02-01 2024-08-08 博迪贺康(北京)生物技术有限公司 一种化合物及其应用
CN116655528B (zh) * 2023-04-28 2025-12-02 宁波百思佳医药科技有限公司 一种氯化1-甲基烟酰铵的制备方法
EP4727544A2 (en) 2023-06-14 2026-04-22 Chromadex Inc. Nicotinamide riboside and derivatives thereof in intravenous formulations and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016530248A (ja) * 2013-07-29 2016-09-29 ザ クイーンズ ユニバーシティ オブ ベルファスト ニコチンアミドリボシドおよびその誘導体を調製する方法
JP2016538271A (ja) * 2013-10-30 2016-12-08 クロマデックス, インコーポレイテッドChromaDex, Inc. 皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288089B1 (en) 1998-12-21 2001-09-11 Michael Zawada Use of kinase inhibitors for treating neurodegenerative diseases
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
CA2421269A1 (en) 2002-08-09 2004-02-09 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US20050096256A1 (en) 2003-07-01 2005-05-05 President And Fellows Of Harvard College Compositions for manipulating the lifespan and stress response of cells and organisms
EP2805719A1 (en) 2005-03-30 2014-11-26 Glaxosmithkline LLC Nicotinamide riboside and analogues thereof
US7345178B2 (en) 2005-08-04 2008-03-18 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
TW200918542A (en) 2007-06-20 2009-05-01 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
AU2009243006B2 (en) 2008-05-01 2013-03-21 Sirtris Pharmaceuticals, Inc. Quinolines and related analogs as sirtuin modulators
BRPI0914006A2 (pt) 2008-07-03 2015-10-27 Sirtris Pharmaceuticals Inc benzimidazóis e análogos relacionados como moduladores de sirtuína
CA2738794C (en) 2008-09-29 2016-01-05 Sirtris Pharmaceuticals, Inc. Chromenone analogs as sirtuin modulators
CN102388054B (zh) 2008-12-19 2015-03-04 西特里斯药业公司 噻唑并吡啶沉默调节蛋白调节剂的化合物
WO2011059839A1 (en) 2009-10-29 2011-05-19 Sirtris Pharmaceuticals, Inc. Bicyclic pyridines and analogs as sirtuin modulators
JP2014530870A (ja) 2011-10-20 2014-11-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
KR20140077963A (ko) 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
US20140288052A1 (en) 2011-10-20 2014-09-25 GlaxoSmithKline, LLC Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016530248A (ja) * 2013-07-29 2016-09-29 ザ クイーンズ ユニバーシティ オブ ベルファスト ニコチンアミドリボシドおよびその誘導体を調製する方法
JP2016538271A (ja) * 2013-10-30 2016-12-08 クロマデックス, インコーポレイテッドChromaDex, Inc. 皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ADVANCED DRUG DELIVERY REVIEWS, vol. VOL:48, NR:1, JPN6019025727, 2001, pages 27 - 42, ISSN: 0004070604 *
FRANCHETTI P; PASQUALINI M; ET AL: "STEREOSELECTIVE SYNTHESIS OF NICOTINAMIDE BETA-RIBOSIDE AND NUCLEOSIDE ANALOGS", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. VOL:14, NR:18, JPN5017004697, 20 September 2004 (2004-09-20), NL, pages 4655 - 4658, ISSN: 0004070601 *
JARMAN M; ROSS W C J: "4-SUBSTITUTED NICOTINIC ACIDS AND NICOTINAMIDES. PART II. THE PREPARATION OF 以下備考", JOURNAL OF THE CHEMICAL SOCIETY C: ORGANIC, vol. NR:2, JPN5017004695, 1969, pages 199 - 203, ISSN: 0004215919 *
KAM B L; OPPENHEIMER N J: "SYNTHESIS OF A NEW CLASS OF D-ALDOPENTOFURANOSYLAMINES, THE 5-O-TRITYL-D-ALDOPENTOFURANOSYLAMINES", CARBOHYDRATE RESEARCH, vol. 77, JPN5017004696, 1979, GB, pages 275 - 280, ISSN: 0004215920 *
SHINJI TANIMORI; TAKESHI OHTA; MITSUNORI KIRIHATA: "AN EFFICIENT CHEMICAL SYNTHESIS OF NICOTINAMIDE RIBOSIDE (NAR) AND ANALOGUES", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. VOL:12, NR:8, JPN5017004699, 1 April 2002 (2002-04-01), pages 1135 - 1137, ISSN: 0004070603 *
YANG T; ET AL: "SYNTHESES OF NICOTINAMIDE RIBOSIDE AND DERIVATIVES: EFFECTIVE AGENTS FOR INCREASING 以下備考", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. VOL:50, NR:26, JPN5017004698, 2007, US, pages 6458 - 6461, ISSN: 0004070602 *
平山令明編, 有機化合物結晶作製ハンドブック −原理とノウハウ−, JPN6011053065, 25 July 2008 (2008-07-25), pages 57 - 84, ISSN: 0004215921 *
浅原 照三, 溶剤ハンドブック, JPN6011026738, 1985, pages 47 - 51, ISSN: 0004215922 *
芹澤一英, 医薬品の多形現象と晶析の化学, JPN6015027444, 2002, pages 273 - 278, ISSN: 0004215923 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021506898A (ja) * 2017-12-22 2021-02-22 エリシウム ヘルス，インコーポレーテッド ニコチンアミドリボシドクロリドの結晶形態
JP2022541058A (ja) * 2019-07-19 2022-09-21 バイオシント アクチェンゲゼルシャフト ニコチンアミドリボフラノシド塩の製造方法、ニコチンアミドリボフラノシド塩自体、およびその使用
JP2025028117A (ja) * 2019-07-19 2025-02-28 バイオシント アクチェンゲゼルシャフト ニコチンアミドリボフラノシド塩の製造方法、ニコチンアミドリボフラノシド塩自体、およびその使用
JP7675061B2 (ja) 2019-07-19 2025-05-12 バイオシント アクチェンゲゼルシャフト ニコチンアミドリボフラノシド塩の製造方法、ニコチンアミドリボフラノシド塩自体、およびその使用
JP2023510034A (ja) * 2020-04-03 2023-03-10 深▲せん▼市迪克曼科技開発有限公司 ニコチンアミドリボースの有機酸塩、その組成物及び製造方法
JP7319744B2 (ja) 2020-04-03 2023-08-02 深▲せん▼市迪克曼科技開発有限公司 ニコチンアミドリボースの有機酸塩、その組成物及び製造方法
AU2020440743B2 (en) * 2020-04-03 2024-02-15 Shenzhen Dieckmann Tech Co. Ltd Organic acid salt of nicotinamide riboside, composition thereof and preparation method therefor
JP2022542546A (ja) * 2020-06-19 2022-10-05 ボンタック バイオエンジニアリング（シェンゼン） カンパニー リミテッド ニコチンアミドを原料としてニコチンアミドモノヌクレオチドを調製する方法
JP7213603B2 (ja) 2020-06-19 2023-01-27 ボンタック バイオエンジニアリング（シェンゼン） カンパニー リミテッド ニコチンアミドを原料としてニコチンアミドモノヌクレオチドを調製する方法
JP2024503442A (ja) * 2021-01-19 2024-01-25 バイオシント アクチェンゲゼルシャフト 塩メタセシスによるニコチンアミドリボフラノシド塩の製造方法、そのトシレート塩の結晶形態及びそのクロリド：ヨージド塩の共結晶化した形態
JP7761652B2 (ja) 2021-01-19 2025-10-28 バイオシント アクチェンゲゼルシャフト 塩メタセシスによるニコチンアミドリボフラノシド塩の製造方法、そのトシレート塩の結晶形態及びそのクロリド：ヨージド塩の共結晶化した形態

Also Published As

Publication number Publication date
WO2015186068A1 (en) 2015-12-10
KR20170012449A (ko) 2017-02-02
RU2016149764A (ru) 2018-07-17
US10316054B2 (en) 2019-06-11
AU2015270130A1 (en) 2016-12-15
US20170204131A1 (en) 2017-07-20
CA2950727A1 (en) 2015-12-10
EP3149016A1 (en) 2017-04-05
CN106536535A (zh) 2017-03-22
MX2016015997A (es) 2017-04-05

Similar Documents

Publication Publication Date Title
US10316054B2 (en) Preparation and use of crystalline beta-D-nicotinamide riboside
JP6559713B2 (ja) ニコチンアミドリボシド類似体ならびにその医薬組成物および使用
EP2805719A1 (en) Nicotinamide riboside and analogues thereof
AU2006269459B2 (en) Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US20100168084A1 (en) Therapeutic compounds and related methods of use
ES2397275T3 (es) Derivados de imidazopiridina como agentes moduladores de la sirtuína
US20110009496A1 (en) Resveratrol formulations
CA3035210A1 (en) Fused bicyclic sgc stimulators
JP2008535790A (ja) サーチュインモジュレーターであるｎ−フェニルベンズアミド誘導体
EP1856099A2 (en) Acridine and quinoline derivatives as sirtuin modulators
AU2015317823A1 (en) sGC stimulators
WO2006094235A1 (en) Fused heterocyclic compounds and their use as sirtuin modulators
WO2006078941A2 (en) Novel sirtuin activating compounds and methods of use thereof
TW200914437A (en) FAAH inhibitors
JP2009521408A (ja) Ｃｄｃ２様キナーゼ（ＣＬＫ）のモジュレータおよびその使用方法
WO2011058766A1 (en) Aryl carboxamide derivatives as ttx-s blockers
WO2009158646A1 (en) Therapeutic compunds and related methods of use
WO2006094246A2 (en) N-arylmethyl benzamide sirtuin modulators
WO2006094233A1 (en) N,n'-dicyclic isothiourea sirtuin modulators
HK40013531A (en) Treatment of cns diseases with sgc stimulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180604

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191007

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200218